Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 14;24(8):7289.
doi: 10.3390/ijms24087289.

Metal-Based Complexes in Cancer

Affiliations
Editorial

Metal-Based Complexes in Cancer

Claudia Riccardi et al. Int J Mol Sci. .

Abstract

Metal-based drugs have attracted growing interest in biomedicine [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Anthony E.J., Bolitho E.M., Bridgewater H.E., Carter O.W.L., Donnelly J.M., Imberti C., Lant E.C., Lermyte F., Needham R.J., Palau M., et al. Metallodrugs are unique: Opportunities and challenges of discovery and development. Chem. Sci. 2020;11:12888–12917. doi: 10.1039/D0SC04082G. - DOI - PMC - PubMed
    1. Ndagi U., Mhlongo N., Soliman M.E. Metal complexes in cancer therapy—An update from drug design perspective. Drug Des. Devel. Ther. 2017;11:599–616. doi: 10.2147/DDDT.S119488. - DOI - PMC - PubMed
    1. Paprocka R., Wiese-Szadkowska M., Janciauskiene S., Kosmalski T., Kulik M., Helmin-Basa A. Latest developments in metal complexes as anticancer agents. Coord. Chem. Rev. 2022;452:214307. doi: 10.1016/j.ccr.2021.214307. - DOI
    1. Lucaciu R.L., Hangan A.C., Sevastre B., Oprean L.S. Metallo-drugs in cancer therapy: Past, present and future. Molecules. 2022;27:6485. doi: 10.3390/molecules27196485. - DOI - PMC - PubMed
    1. Vértiz G., García-Ortuño L.E., Bernal J.P., Bravo-Gómez M.E., Lounejeva E., Huerta A., Ruiz-Azuara L. Pharmacokinetics and hematotoxicity of a novel copper-based anticancer agent: Casiopeina III-Ea, after a single intravenous dose in rats. Fundam. Clin. Pharmacol. 2014;28:78–87. doi: 10.1111/j.1472-8206.2012.01075.x. - DOI - PubMed

Publication types